The present invention relates to new hyaluronic acid binding proteins. The invention refers to new engineered fusion proteins for use in treating disorders of the eye or the joints. The fusion proteins comprise a subunit that specifically binds to hyaluronic acid. In addition to the hyaluronic acid binding protein, the new fusion proteins comprise a protein therapeutically effective in diseases of the eye or of joints. The fusion proteins are particularly well-suited for medical applications that require extended half-life of eye specific therapeutic proteins.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
The present invention relates to novel proteins that specifically bind to the ferritin. The novel proteins of the present invention are advanced and powerful tools because they allow precise purification methods of ferritin, for example via affinity chromatography. Further, the binding protein for ferritin is useful for methods to analyze the presence of ferritin.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Analytical, biological, chemical, chromatographical biochemical, diagnostic, therapeutic substances, active ingredients, and/or compositions, in particular containing proteins, polypeptides, peptides, for diagnostic and therapeutic applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research and development work for purification, identification, further development and application of analytical, biochemical, pharmaceutical, diagnostic or therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Services and research and development work in the field of chromatography; Services and research and development work in the field of purification, identification, screening and production of analytical, biochemical, pharmaceutical, diagnostic and therapeutic goods, in particular proteins, polypeptides, peptides, antibodies, fusion proteins, enzymes, hormones, blood factors, vaccines, virus vectors, virus-like particles, cells, RNA and test kits; Services and research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, biotechnological, biochemical or genetic methods.
The invention relates to fusion proteins that comprise at least one serum albumin binding protein. The fusion proteins of the present invention can be characterized by (i) the high thermal stability (in particular, a Tm above 70 °C), (ii) the high binding affinity for human, mouse, and rat serum albumin (in the two digit nanomolar range), and (iii) the long stability in human and mouse serum (at least 48 h). The invention also relates to the use of the fusion protein or of compositions comprising the fusion protein for medical applications.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
7.
SPECIFIC BACULOVIRUS MAJOR ENVELOPE GLYCOPROTEIN GP64 BINDING PROTEINS
gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
8.
Affinity ligands for the purification and detection of ubiquitin muteins
The present invention relates to novel affinity ligands for the affinity purification of ubiquitin muteins. In particular, the alkaline stable affinity ligands are useful for affinity chromatography purification and detection of a ubiquitin mutein (such as Affilin® protein). The novel affinity ligands for a ubiquitin mutein are based on artificial mosaic proteins of Protein A-like structure. The affinity ligands of the invention can be used for the purification and detection of ubiquitin muteins.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
9.
NOVEL HUMAN PROGRAMMED DEATH LIGAND 1 (PD-L1) SPECIFIC BINDING MOLECULES
The present invention relates to new ubiquitin derived molecules that are specific for Programmed Death Ligand 1 (PD-L1). The PD-L1 specific molecules of the invention inhibit the interaction between PD1 and PD-L1. The invention further refers to PD-L1 specific Affilin® proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
10.
FUSION PROTEINS WITH SPECIFITY FOR TYPE II COLLAGEN AND VEGF-A FOR THE TREATMENT OF EYE DISEASES
The present invention relates to new engineered fusion proteins with for use in treating disorders of the eye. In particular, the new fusion proteins are capable of binding both VEGF-A and Type II collagen. The fusion proteins comprise a subunit that specifically binds to Type II collagen which is a major component of the fibrillary structure of the vitreous humor of the eye. In addition to the Type II collagen binding protein, the new fusion proteins comprise a protein specific for VEGF-A and therapeutically effective in eye diseases. The invention further relates to the new fusion proteins for a use in the treatment of neovascular eye diseases.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention relates to novel ligands for affinity chromatography, in particular purification of antibodies. The novel ligands are immunoglobulin (Ig) binding proteins with superior properties for highly efficient purification methods for antibodies (immunoglobulins). The invention further relates to affinity matrices comprising the ligands of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
12.
NOVEL PROTEINS WITH HIGH BINDING AFFINITY TO PROGRAMMED DEATH LIGAND 1 (PD-L1)
The present invention relates to new proteins that are specific for Programmed (Cell) Death Ligand 1 (PD-L1). The PD-L1 specific proteins of the invention bind with high affinity to human and mouse PD-L1. The invention further refers to PD-L1 specific proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 specific binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
13.
BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The invention relates to a fusion protein that comprises at least one albumin binding moiety and further comprises a tumor targeting moiety. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active component. Further aspects of the invention cover the use of these type II collagen binding proteins in medicine.
The present invention relates to novel proteins that specifically bind to complement factor H (CFH). The present invention further relates to methods of production of CFH, in particular purification of CFH. The novel CFH binding ligands of the present invention are advanced and powerful tools because they allow methods of purification of CFH via affinity chromatography.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
17.
SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS
The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
18.
BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona vims 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
C07K 16/10 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
The present invention relates to novel proteins that specifically bind to the ferritin. The novel proteins of the present invention are advanced and powerful tools because they allow precise purification methods of ferritin, for example via affinity chromatography. Further, the binding protein for ferritin is useful for methods to analyze the presence of ferritin.
The present invention relates to novel engineered artificial immunoglobulin (Ig) binding polypeptides comprising three domains and two linkers. The invention further relates to affinity matrices comprising these artificial Ig binding molecules of the invention. The novel Ig binding proteins are particularly useful for the affinity purification of proteins requiring elution at a higher pH (in particular higher than pH 4.2). The invention also relates to a use of the novel Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the novel Ig binding proteins of the invention.
The present invention relates to new ubiquitin derived molecules that bind specific to Fibroblast Activation Protein (FAP). The invention further refers to FAP binding ubiquitin derived molecules (Affilin®) proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover such FAP binding proteins for a use in medicine, for example, for a use in diagnosis (including imaging) or treatment of FAP related tumors.
gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Scientific, technological, and industrial research services all in the field of half-life modifying domains; scientific, technological, and industrial research services conducted in molecular biology, biotechnology and biochemical laboratories all in the field of half-life modifying domains
24.
AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (sFGFR3)
The present invention relates to the field of protein purification and relates in particular to novel proteins that bind to the soluble part of fibroblast growth factor receptor 3 (sFGFR3). The invention further relates to fusion proteins comprising novel proteins that bind to sFGFR3. In addition, the invention relates to affinity matrices comprising the sFGFR3 binding proteins of the invention. The invention also relates to a use of these sFGFR3 binding proteins or affinity matrices for affinity purification of sFGFR3 nd to methods of affinity purification of sFGFR3 using the sFGFR3 binding proteins of the invention. Further uses relate to analytical methods for the determination of SFGFR3 in liquids.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
25.
Binding proteins for the enzyme acid alpha glucosidase (GAA) and uses thereof
The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12N 15/52 - Gènes codant pour des enzymes ou des proenzymes
G01N 33/573 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour enzymes ou isoenzymes
26.
AFFINITY LIGANDS FOR THE PURIFICATION AND DETECTION OF UBIQUITIN MUTEINS
The present invention relates to novel affinity ligands for the affinity purification of ubiquitin muteins. In particular, the alkaline stable affinity ligands are useful for affinity chromatography purification and detection of a ubiquitin mutein (such as Affilin® protein). The novel affinity ligands for a ubiquitin mutein are based on artificial mosaic proteins of Protein A-like structure. The affinity ligands of the invention can be used for the purification and detection of ubiquitin muteins..
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
27.
FUSION PROTEINS WITH SPECIFITY FOR TYPE II COLLAGEN AND VEGF-A FOR THE TREATMENT OF EYE DISEASES
The present invention relates to new engineered fusion proteins with for use in treating disorders of the eye. In particular, the new fusion proteins are capable of binding both VEGF- A and Type II collagen. The fusion proteins comprise a subunit that specifically binds to Type II collagen which is a major component of the fibrillary structure of the vitreous humor of the eye. In addition to the Type II collagen binding protein, the new fusion proteins comprise a protein specific for VEGF-A and therapeutically effective in eye diseases. The invention further relates to the new fusion proteins for a use in the treatment of neovascular eye diseases.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 14/78 - Peptides du tissu connectif, p. ex. collagène, élastine, laminine, fibronectine, vitronectine ou globuline insoluble à froid [CIG]
The present invention relates to new ubiquitin derived molecules that are specific for Programmed Death Ligand 1 (PD-L1). The PD-L1 specific molecules of the invention inhibit the interaction between PD1 and PD-L1. The invention further refers to PD-L1 specific Affilin® proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PD-L1 binding proteins in medicine, for example, in diagnosis and therapy of PD-L1 related cancer.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
The present invention relates to novel proteins that specifically bind to complement factor H (CFH). The present invention further relates to methods of production of CFH, in particular purification of CFH. The novel CFH binding ligands of the present invention are advanced and powerful tools because they allow methods of purification of CFH via affinity chromatography.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/00 - Préparations médicinales contenant des peptides
The present invention relates to new type II collagen alpha I chain specific binding proteins. The invention further refers to type II collagen binding proteins further fused to or conjugated to a therapeutically or diagnostically active component. Further aspects of the invention cover the use of these type II collagen binding proteins in medicine.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Biological, diagnostic, therapeutic, biochemical substances, active agents, and/or compositions for human medical, veterinary, and/or diagnostic use, in particular containing proteins, polypeptides, peptides or parts thereof; Pharmaceutical and veterinary preparations; Therapeutic agents [medical]; Biochemical therapeutic active agents. Scientific, technological and industrial services, Scientific, technological and industrial research, Especially, Relating to the following sectors: Pharmaceutical, therapeutic and diagnostic field; Services and research work for the further development and application of pharmaceutical, diagnostic and therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of human medical and veterinary diagnostics and treatment using molecular biological, biotechnological or biochemical, genetic engineering methods, and in the field of development of analytic, biochemical, pharmaceutical and diagnostic goods and test methods and test kits.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Biological, diagnostic, therapeutic, biochemical substances, active agents, and/or compositions for human medical, veterinary, and/or diagnostic use, in particular containing proteins, polypeptides, peptides or parts thereof; Pharmaceutical and veterinary preparations; Therapeutic agents [medical]; Biochemical therapeutic active agents. Scientific services and research, Technological services and research, Industrial services, Industrial research, Especially, Relating to the following sectors: Pharmacy, Biochemistry, Treatment, Diagnostics; Services and research work for the further development and application of biochemical, pharmaceutical, diagnostic and therapeutic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of human medical and veterinary diagnostics and treatment using molecular biological, biotechnological or biochemical, genetic engineering methods, and in the field of development of analytic, biochemical, pharmaceutical and diagnostic goods and test methods and test kits.
34.
NOVEL FOLR1 SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
35.
IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/305 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F)
36.
Triple-helical polypeptides lacking binding affinity for the Fc domain of immunoglobulin and uses thereof
The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, in particular purification methods, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services in the form of research for purification, identification, further development and application of analytical, biochemical, pharmaceutical or diagnostic goods; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, biotechnological, biochemical, genetic engineering methods, and in the field of purification, identification, screening and development of analytic, biochemical, pharmaceutical, diagnostic goods and test methods and test kits.
41.
IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains having highly hydrophobic amino acids with branched side chains (Iso, Leu, Val), or aromatic amino acids (Tyr, Phe, or Trp) corresponding to position 4 or 6 or 8 of the Ig binding protein of SEQ ID NO: 1 or functionally similar proteins. The novel proteins have superior properties for highly efficient purification methods for antibodies (immunoglobulins), for example, the proteins have high binding capacity and high chemical stability. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 14/315 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Streptococcus (G), p. ex. Enterocoques
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
42.
SERUM STABLE BINDING PROTEINS FOR HUMAN HER2 FOR THERANOSTIC APPLICATIONS
The present disclosure relates to new serum stable non-immunoglobulin binding proteins based on ubiquitin scaffold that are highly specific for membrane-bound receptor tyrosine kinase (Her2). The disclosure provides novel specific recombinant Her2 binding proteins with high serum stability essentially combined with high temperature stability and high affinity for Her2 for uses in medical applications for diagnosis or therapy of cancer with Her2 overexpression, in particular, for radiopharmaceutical applications.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
43.
BINDING PROTEIN SPECIFIC FOR THE SPIKE PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONA VIRUS 2 (SARS-COV-2)
The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
The present invention relates to novel proteins that specifically bind to the spike protein or domains thereof of the severe acute respiratory syndrome corona virus 2 (SARS-Cov-2) or variants of SARS-Cov-2. The proteins of the present invention represent advanced and powerful tools, for example for the purification of the virus or a vaccine for the virus, by virtue of said binding affinity for spike protein or domains of the spike protein of SARS-Cov-2 or variants thereof. Thus, the novel proteins of the present invention are particularly advantageous because they allow precise capturing of proteins or particles comprising spike proteins, S1 domain, and/or RBD in affinity chromatography. Further, the novel proteins of the present invention can be used in medical applications caused by or related to SARS-Cov-2 or variants thereof.
The present invention relates to novel engineered artificial immunoglobulin (Ig) binding polypeptides comprising three domains and two linkers. The invention further relates to affinity matrices comprising these artificial Ig binding molecules of the invention. The novel Ig binding proteins are particularly useful for the affinity purification of proteins requiring elution at a higher pH (in particular higher than pH 4.2). The invention also relates to a use of the novel Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the novel Ig binding proteins of the invention.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 1/12 - Procédés généraux de préparation de peptides par hydrolyse
46.
AFFINITY LIGAND FOR THE SOLUBLE PART OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (SFGFR3)
The present invention relates to the field of protein purification and relates in particular to novel proteins that bind to the soluble part of fibroblast growth factor receptor 3 (sFGFR3). The invention further relates to fusion proteins comprising novel proteins that bind to sFGFR3. In addition, the invention relates to affinity matrices comprising the sFGFR3 binding proteins of the invention. The invention also relates to a use of these sFGFR3 binding proteins or affinity matrices for affinity purification of sFGFR3 and to methods of affinity purification of sFGFR3 using the sFGFR3 binding proteins of the invention. Further uses relate to analytical methods for the determination of SFGFR3 in liquids.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
47.
BINDING PROTEINS FOR THE ENZYME ACID ALPHA GLUCOSIDASE (GAA) AND USES THEREOF
The present invention relates to the field of protein purification and relates in particular to novel proteins that bind specifically to acid alpha glucosidase (GAA). The invention further relates to fusion proteins comprising novel proteins that bind specifically to GAA. In addition, the invention relates to affinity matrices comprising the GAA binding proteins of the invention. The invention also relates to a use of these GAA binding proteins or affinity matrices for affinity purification of GAA and to methods of affinity purification of GAA using the GAA binding proteins of the invention. Further uses relate to analytical methods for the determination of GAA in liquids.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
48.
Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
49.
NOVEL PSMA SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
50.
IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
51.
NOVEL FOLR1 SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
52.
Populations of polypeptides having a triple-helical structure
Provided are populations of polypeptides, wherein each member of the population of polypeptides includes or is an amino sequence as set forth in SEQ ID NO: 5 or SEQ ID NO: 6. Also provided are methods for identifying polypeptides that bind to pre-selected target molecules, which in some embodiments can include providing a population of polypeptides as described herein, contacting the population of polypeptides with a pre-selected target molecule, and identifying a complex comprising at least one member of the population of polypeptides bound to the pre-selected target molecule; and populations of nucleic acid molecules that encode the presently disclosed populations of polypeptides.
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
53.
NOVEL TRIPLE-HELICAL POLYPEPTIDES LACKING BINDING AFFINITY FOR THE FC DOMAIN OF IMMUNOGLOBULIN AND USES THEREOF
The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Diagnostic, therapeutic, analytical, biological, chemical,
biochemical substances, active agents, and/or compositions
for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and
industrial research, in particular in the pharmaceutical,
diagnostic, analytical or biochemical field; research and
development services in the field of identification and
further use of biochemical, pharmaceutical, analytical or
diagnostic products; molecular biological, biotechnological,
biochemical or pharmaceutical laboratory services; research
and development in the field of medical and veterinary
diagnostics and treatment using molecular biological,
genetic engineering, biotechnological or biochemical
methods, and research and development services in the field
of identification and screening of pharmaceutically active
components, and test methods and test kits.
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 16/06 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux provenant de sérum
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
56.
FUSION PROTEINS WITH SPECIFICITY FOR ED-B AND LONG SERUM HALF-LIFE FOR DIAGNOSIS OR TREATMENT OF CANCER
The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
57.
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin @) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
G01N 33/533 - Production de composés immunochimiques marqués avec un marqueur fluorescent
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical and/or chromatographic substances, active ingredients and/or compositions, in particular containing proteins, polypeptides, peptides or parts thereof, in particular proteins, peptides or polypeptides fused to antibodies or antibody fragments, for industrial and scientific applications, not for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical and biochemical substances, active ingredients and/or compositions containing proteins, polypeptides and peptides, in particular proteins, peptides or polypeptides fused to antibodies or antibody fragments, for medical and veterinary applications. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic, biotechnological or biochemical methods.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions, namely, diagnostic preparations for medical and veterinary use, therapeutic preparations for medical and veterinary use, pharmaceutical preparations for the medical treatment of cancer, metabolic, inflammatory, skin, eye and cardiovascular diseases, and chemical reagents for medical or veterinary purposes Scientific, technological and industrial analysis services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; scientific and technological services and research relating thereto for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and research and development services in the field of identification, screening of pharmaceutically active components, and test methods and test kits
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and/or chromatographic
preparations, active agents, and/or compositions, in
particular containing proteins, polypeptides, peptides, for
industrial and scientific applications, including laboratory
analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical,
biochemical substances, active agents, and/or compositions
for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial analysis service
and research, in particular in the pharmaceutical,
diagnostic, analytical or biochemical field; scientific and
technological services and research for identification,
further development and use of biochemical, pharmaceutical,
analytical or diagnostic products; molecular biological,
biotechnological, biochemical or pharmaceutical laboratory
services; research and development in the field of medical
and veterinary diagnostics and treatment using molecular
biological, genetic engineering, biotechnological or
biochemical methods, and in the field of identification,
screening and development of pharmaceutically active
components, and test methods and test kits.
61.
Immunoglobulin-binding proteins and their use in affinity purification
The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The disclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and chromatographic preparations, active agents, and compositions, namely, proteins, polypeptides, and peptide substrates in raw form for scientific research, in particular for analysis of polypeptide, protein and peptide interaction, all of the foregoing not for medical or veterinary use Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and compositions, namely, diagnostic preparations for medical and veterinary purposes Scientific and technological analysis services, namely, scientific research in the pharmaceutical, diagnostic, analytical and biochemical field; scientific and technological services, namely, scientific research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; scientific laboratory services in the fields of molecular biological, biotechnological, biochemical or pharmaceutical products; scientific research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits
63.
Binding proteins based on di-ubiquitin muteins and methods for generation
The present invention refers to new binding proteins based on di-ubiquitin modified in 12, 13, or 14 positions selected from positions R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 of di-ubiquitin and being able to bind specifically with high affinity to selected targets. Furthermore, the invention provides a method for the generation of said binding proteins. In addition, libraries encoding for said binding proteins based on di-ubiquitin muteins modified in 12, 13, or 14 positions selected from R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 are provided.
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
A61K 38/00 - Préparations médicinales contenant des peptides
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and industrial research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific and technological services and research and industrial research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding5 proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and/or chromatographic preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemische, biologische, analytische, und/oder chromatographische Erzeugnisse, Wirkstoffe, und/oder Zusammensetzungen, insbesondere enthaltend Proteine, Polypeptide, Peptide, für gewerbliche und wissenschaftliche Anwendungen, wie Laboranalysen, nicht zur humanmedizinischen und veterinärmedizinischen Verwendung. Diagnostische, therapeutische, analytische, biologische, chemische, biochemische Erzeugnisse, Wirkstoffe, und/oder Zusammensetzungen zur humanmedizinischen, veterinärmedizinischen, und/oder diagnostischen Anwendung. Wissenschaftliche, technologische und industrielle Dienstleistungen und Forschung, insbesondere auf pharmazeutischem, diagnostischem, analytischem oder biochemischem Gebiet; Dienstleistungen und Forschungsarbeiten zur Identifizierung, Weiterentwicklung und Anwendung von biochemischen, pharmazeutischen, analytischen oder diagnostischen Produkten; Dienstleistungen eines molekularbiologischen, biotechnologischen, biochemischen oder pharmazeutischen Labors; Forschungs- und Entwicklungsarbeiten auf dem Gebiet der humanmedizinischen und veterinärmedizinischen Diagnostik und Therapie mittels molekularbiologischer, gentechnischer, biotechnologischer, oder biochemischer Methoden sowie auf dem Gebiet der Identitifizierung, des Screenings und der Entwicklung pharmazeutisch wirksamer Verbindungen sowie Testverfahren und Testkits.
The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/00 - Préparations médicinales contenant des peptides
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and/or chromatographic
preparations, active agents, and/or compositions, in
particular containing proteins, polypeptides, peptides, for
industrial and scientific applications, including laboratory
analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical,
biochemical substances, active agents, and/or compositions
for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial analysis services
and research, in particular in the pharmaceutical,
diagnostic, analytical or biochemical field; scientific and
technological services and research for identification,
further development and use of biochemical, pharmaceutical,
analytical or diagnostic products; molecular biological,
biotechnological, biochemical or pharmaceutical laboratory
services; research and development in the field of medical
and veterinary diagnostics and treatment using molecular
biological, genetic engineering, biotechnological or
biochemical methods, and in the field of identification,
screening and development of pharmaceutically active
components, and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic
substances, active agents, and/or compositions, in
particular containing proteins, polypeptides, peptides, or
parts therefor, for industrial and scientific applications,
including laboratory analysis, other than for medical and
veterinary use. Diagnostic, therapeutic, analytical, biological, chemical,
biochemical substances, active agents, and/or compositions
for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial analysis services
and research, in particular in the pharmaceutical,
diagnostic, analytical or biochemical field; scientific and
technological services and research relating thereto for
identification, further development and use of biochemical,
pharmaceutical, analytical or diagnostic products; molecular
biological, biotechnological, biochemical or pharmaceutical
laboratory services; research and development in the field
of medical and veterinary diagnostics and treatment using
molecular biological, genetic engineering, biotechnological
or biochemical methods, and in the field of identification,
screening and development of pharmaceutically active
components, and test methods and test kits.
72.
TARGETED COMPOUNDS FOR THE SITE-SPECIFIC COUPLING OF CHEMICAL MOIETIES COMPRISING A PEPTIDE LINKER
The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin ®) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and/or chromatographic
preparations, active agents, and/or compositions, in
particular containing proteins, polypeptides, peptides, for
industrial and scientific applications, including laboratory
analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical,
biochemical substances, active agents, and/or compositions
for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and
research, in particular in the pharmaceutical, diagnostic,
analytical or biochemical field; services and research for
identification, further development and use of biochemical,
pharmaceutical, analytical or diagnostic products; molecular
biological, biotechnological, biochemical or pharmaceutical
laboratory services; research and development in the field
of medical and veterinary diagnostics and treatment using
molecular biological, genetic engineering, biotechnological
or biochemical methods, and in the field of identification,
screening and development of pharmaceutically active
components, and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, namely, polypeptides, proteins or peptides in raw form for scientific research, namely, for analysis of polypeptide, protein and peptide interaction, all of the foregoing not for medical or veterinary use Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions, namely, diagnostic preparations for medical [ and veterinary ] use, therapeutic preparations for medical [ and veterinary use, namely, medicated bath preparations, ] pharmaceutical preparations for the medical treatment of cancer, metabolic, inflammatory, skin, eye and cardiovascular diseases, and chemical reagents for medical or veterinary purposes Scientific and technological services, namely, scientific research and analysis in the fields of pharmaceutical, diagnostic, analytical or biochemical substances; scientific and technological services, namely, scientific research in the fields of the identification, further development, and use of biochemical, pharmaceutical, analytical and diagnostic products; scientific laboratory services in the fields of molecular biological, biotechnological, biochemical or pharmaceutical products; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits
The present invention relates to novel fusion proteins for capturing of cells. The invention features fusion proteins comprising a non-lg protein that is capable of binding a cell-surface target, at least one cleavage site for the release of the cells attached to fusion proteins, at least one peptide linker covalently connecting the non-lg protein and a cleavage site, and a coupling moiety enabling attachment of the fusion protein to a solid support. The invention also relates to the use of these fusion proteins in applications for capturing cells and to methods of capturing cells. The invention further relates to nucleic acid molecules encoding these non-lg fusion proteins, to vectors comprising these nucleic acid molecules, and to host cells comprising these proteins, nucleic acid molecules, or vectors. The invention relates to methods for the production of these fusion proteins.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 17/00 - Peptides fixés sur un support ou immobilisésLeur préparation
C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, namely, polypeptides, proteins or peptides in raw form for scientific research, namely, for analysis of polypeptide, protein and peptide interaction, all of the foregoing not for medical or veterinary use Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions, namely, diagnostic preparations for medical [ and veterinary ] use, therapeutic preparations for medical [ and veterinary use, namely, medicated bath preparations, ] pharmaceutical preparations for the medical treatment of cancer, metabolic, inflammatory, skin, eye and cardiovascular diseases, and chemical reagents for medical or veterinary purposes Scientific and technological services, namely, scientific research and analysis in the fields of pharmaceutical, diagnostic, analytical or biochemical substances; scientific and technological services, namely, scientific research in the fields of the identification, further development, and use of biochemical, pharmaceutical, analytical and diagnostic products; scientific laboratory services in the fields of molecular biological, biotechnological, biochemical or pharmaceutical products; research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals, biological, analytical, and/or chromatographic preparations, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, for industrial and scientific applications, including laboratory analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemical, biological, analytical, and/or chromatographic substances, active agents, and/or compositions, in particular containing proteins, polypeptides, peptides, or parts therefor, for industrial and scientific applications, including laboratory analysis, other than for medical and veterinary use. Diagnostic, therapeutic, analytical, biological, chemical, biochemical substances, active agents, and/or compositions for medical, veterinary, and/or diagnostic use. Scientific, technological and industrial services and research, in particular in the pharmaceutical, diagnostic, analytical or biochemical field; Services and research for identification, further development and use of biochemical, pharmaceutical, analytical or diagnostic products; Molecular biological, biotechnological, biochemical or pharmaceutical laboratory services; Research and development in the field of medical and veterinary diagnostics and treatment using molecular biological, genetic engineering, biotechnological or biochemical methods, and in the field of identification, screening and development of pharmaceutically active components, and test methods and test kits.
79.
HER2 BINDING PROTEINS BASED ON DI-UBIQUITIN MUTEINS
The present invention relates to new Her2 binding molecules based on di-ubiquitin muteins. The invention further refers to Her2 binding proteins optionally fused or conjugated to a moiety modulating pharmacokinetics or to a therapeutically or diagnostically active component. The invention further relates to the use of these Her2 binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
80.
NOVEL BINDING PROTEINS BASED ON DI-UBIQUITIN MUTEINS AND METHODS FOR GENERATION
The present invention refers to new binding proteins based on di-ubiquitin modified in 12, 13, or 14 positions selected from positions R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 of di- ubiquitin and being able to bind specifically with high affinity to selected targets. Furthermore, the invention provides a method for the generation of said binding proteins. In addition, libraries encoding for said binding proteins based on di-ubiquitin muteins modified in 12, 13, or 14 positions selected from R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 are provided.
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
81.
NOVEL IMMUNOGLOBULIN-BINDING PROTEINS AND THEIR USE IN AFFINITY PURIFICATION
The present disclosure relates to non-natural binding proteins comprising one or more non-natural immunoglobulin (Ig) binding domains wherein at least one non-natural lg-binding domain comprises the amino acid sequence X1 X2X3XiXsX5X7 XsQQX11AFYX1sX15LX1 sX19PX21 LX23X24X2sQRX28X2gf IQSLKDDPSXio SXi2Xi3Xi4LXi5EAXigKLXs2Xs3Xs4QXs5PX. The idisclosure also relates to compositions such as affinity matrices comprising the non-natural Ig-binding proteins of the invention. Use of these Ig-binding proteins or of the compositions for affinity purification of immunoglobulins and to methods of affinity purification.
C07K 16/12 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
82.
NOVEL BINDING PROTEINS COMPRISING A UBIQUITIN MUTEIN AND ANTIBODIES OR ANTIBODY FRAGMENTS
The present invention relates novel binding molecules comprising a ubiquitin mutein (Affilin® ) and a monoclonal antibody or antibody fragment. The invention refers to bispecific and/or bivalent binding proteins or to a therapeutically or diagnostically active component. The invention further relates to the use of these binding proteins ' medicine, preferably for use in the treatment of cancer or autoimmune disorders.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
84.
Dimeric binding proteins based on modified ubiquitins
The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
85.
Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands
The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
C40B 50/06 - Procédés biochimiques, p. ex. utilisant des enzymes ou des micro-organismes viables entiers
86.
Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
The present invention refers to novel hetero-multimeric proteins obtained from modified ubiquitin capable of binding the extradomain B of fibronectin (ED-B) with high affinity. Furthermore, the invention refers to fusion proteins comprising said recombinant protein fused to a pharmaceutically and/or diagnostically active component. The invention is further directed to the use of said proteins in medical treatment methods.
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Chemicals used in industry and science,In particular comprising antibody-like proteins or parts thereof or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; Polypeptides and Proteins; Diagnostic and analytical compositions, not for medical or veterinary use; Chemical substances for analysis in laboratories,Not for medical or veterinary use; Biological compositions for laboratories, not for medical or veterinary use; Biological compositions for laboratory analysis and diagnostics. Pharmaceutical and veterinary preparations; Medical therapeutic agents, biochemical therapeutic agents, except preparations containing theophylline; Diagnostic and/or analytical compositions for medical and/or veterinary use; Biological and/or chemical compositions for medical and/or veterinary use. Scientific and industrial research in particular in the biochemical, diagnostic or pharmaceutical fields; Biochemisty or phamaceutical laboratory services; Scientific and technological services and research; Industrial research and analysis; Services and research for the identification and further development of biochemical, pharmaceutical or diagnostic products.
88.
Artificial binding proteins based on a modified alpha helical region of ubiquitin
The present invention is directed to a method for the generation of binding proteins derived from the protein super-family of ubiquitin like proteins with modifications in their alpha helical region as well as to a protein obtainable by said method. Furthermore, the invention provides the use of a protein for the specific recognition, binding and neutralization of a predescribed target molecule, for the detection, quantitative determination, separation and/or for the isolation of a corresponding binding partner and the use of a protein of the invention, for diagnosis, prophylaxis and treatment of diseases in which the corresponding binding partner is directly or indirectly involved.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
89.
Generation of artificial binding proteins on the basis of ubiquitin proteins
The invention relates to modified proteins of the superfamily of “ubiquitin-like proteins”, proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p. ex. des bactéries ou des cellules animalesBibliothèques contenues ou présentées dans des vecteurs, p. ex. des plasmidesBibliothèques contenant uniquement des micro-organismes ou des vecteurs
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
The present invention relates to new EGFR binding molecules based on ubiquitin muteins (Affilin®), preferably Affilin molecules having a characteristic three amino acid residue motif. The invention further refers to EGFR binding molecules that bind to different or non-overlapping epitopes than the anti-EGFR monoclonal antibody Cetuximab. The invention further relates to the use of these EGFR binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention relates to new Her2 binding molecules based on di-ubiquitin muteins. The invention further refers to Her2 binding proteins optionally fused or conjugated to a moiety modulating pharmacokinetics or to a therapeutically or diagnostically active component. The invention further relates to the use of these Her2 binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
92.
NOVEL BINDING PROTEINS BASED ON DI-UBIQUITIN MUTEINS AND METHODS FOR GENERATION
The present invention refers to new binding proteins based on di-ubiquitin modified in 12, 13, or 14 positions selected from positions R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, and T142 of di- ubiquitin and being able to bind specifically with high affinity to selected targets. Furthermore, the invention provides a method for the generation of said binding proteins. In addition, libraries encoding for said binding proteins based on di-ubiquitin muteins modified in 12, 13, or 14 positions selected from R42, I44, H68, V70, R72, L73, R74, K82, L84, Q138, K139, E140, S141, andT142 are provided.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
93.
TARGETED COMPOUNDS FOR THE SITE-SPECIFIC COUPLING OF CHEMICAL MOIETIES COMPRISING A PEPTIDE LINKER
The invention generally relates to targeted compounds for the site-specific coupling of chemical moieties. The present invention features a targeted compound for the coupling of chemical moieties comprising at least one targeting domain capable of binding a target, and at least one linking moiety of up to 80 amino acids, preferably alanine, proline, and serine, and at least one coupling site consisting of cysteine or a cysteine-rich peptide motif (CXC, CXXC, or CXXXC), and wherein said linking moiety connects the targeting domain and a coupling site and/or wherein a linking moiety connects two coupling sites. The invention further features fusion proteins with ubiquitin muteins (Affilin ®) as targeting domain. The invention also relates to the use of the targeted compounds for medical applications, in treatment or diagnosis of diseases.
A61K 47/66 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé l’agent de modification étant un système de pré-ciblage impliquant un peptide ou une protéine pour cibler des cellules spécifiques
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more Ig binding domains with amino acids selected from the group consisting at least of 1I, 11A, 11E, 11I, 35R, 35I, and 42L. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding5 proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
95.
NOVEL TRIPLE-HELICAL POLYPEPTIDES LACKING BINDING AFFINITY FOR THE FC DOMAIN OF IMMUNOGLOBULIN AND USES THEREOF
The present invention relates to the field of protein engineering and purification and relates in particular to novel polypeptides having a triple-helical structure and lacking binding affinity for the Fc domain of immunoglobulin. The invention further relates to uses of the novel non-Fc binding polypeptides in technical applications such as affinity chromatography, as well as in therapy and diagnostics. In addition, the present invention relates to a method of reducing the binding affinity of a polypeptide having a triple-helical structure for the Fc domain of immunoglobulin.
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
96.
IMMUNOGLOBULIN BINDING PROTEINS FOR AFFINITY PURIFICATION
The present invention relates to immunoglobulin (Ig) binding proteins comprising one or more domains. The invention further relates to affinity matrices comprising the Ig binding proteins of the invention. The invention also relates to a use of these Ig binding proteins or affinity matrices for affinity purification of immunoglobulins and to methods of affinity purification using the Ig binding proteins of the invention.
C07K 1/22 - Chromatographie d'affinité ou techniques analogues basées sur des procédés d'absorption sélective
C07K 14/31 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Micrococcaceae (F) provenant de Staphylococcus (G)
97.
NOVEL FOLR1 SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
The present invention relates to new binding proteins that are specific for folate receptor alpha (FOLR1). The invention further refers to FOLR1 binding proteins that further comprises a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these FOLR1 binding proteins in medicine, for example, in diagnosis and therapy of FOLR1 related cancer.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
98.
NOVEL PSMA SPECIFIC BINDING PROTEINS FOR CANCER DIAGNOSIS AND TREATMENT
The present invention relates to new binding proteins that are specific for prostate specific membrane antigen (PSMA). The invention further refers to PSMA binding proteins that further comprise a diagnostically or therapeutically active component. Further aspects of the invention cover the use of these PSMA binding proteins in medicine, for example, in diagnosis and therapy of cancer associated with PSMA expression.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
99.
GENERATION OF ARTIFICIAL BINDING PROTEINS BASED ON UBIQUITIN PROTEINS
The invention relates to modified proteins of the superfamily of "ubiquitin- like proteins", proteins that have a ubiquitin-like fold and fragments or fusion proteins thereof. As a result of said modification, the proteins have a binding affinity with respect to a predetermined binding partner that did not exist previously. The invention also relates to a method for the production and utilization of said proteins.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention refers to a method for identifying hetero-multimeric ubiquitins with binding capability to a ligand. Furthermore, the invention provides DNA libraries encoding for a population of said hetero-multimeric ubiquitins as well as protein libraries obtained by expression of said DNA libraries, cells and phages containing said DNA or proteins, polynucleotides encoding for said fusion proteins and vectors comprising said polynucleotides. Further new binding proteins based on hetero-multimeric ubiquitin being able to bind specifically with high affinity to selected ligands are provided.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p. ex. des bactéries ou des cellules animalesBibliothèques contenues ou présentées dans des vecteurs, p. ex. des plasmidesBibliothèques contenant uniquement des micro-organismes ou des vecteurs
